June 9th 2023
Findings from the phase 3 PhALLCON trial show that ponatinib plus reduced-intensity chemotherapy could be a new standard of care for patients with Philadelphia chromosome–positive acute lymphoblastic leukemia.
February 27th 2023
Ponatinib/Blinatumomab Combo Shows Promising Efficacy and Safety in Ph+ ALLJanuary 20th 2023
Phase 2 study shows ponatinib and blinatumomab to represent a promising chemotherapy-free, hematopoietic stem cell transplant–sparing treatment for patients with Philadelphia chromosome–positive acute lymphocytic leukemia.
CAR T-Cell Combination Demonstrates Efficacy in Pediatric Patients With B-ALLDecember 20th 2022
Treatment with CD19-/CD22-chimeric antigen T-cell therapy demonstrated durable remissions in children with relapsed or refractory B-acute lymphoblastic leukemia, according to a phase 2 study.
Olverembatinib Induces Responses in Patients With Ponatinib-Resistant, T315I-Mutant CML, and Ph-Positive ALLDecember 13th 2022
An early study showed that encouraging responses were elicited with olverembatinib in patients with ponatinib-resistant chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.
FDA Grants Breakthrough Therapy Designation to SNDX-5613 for R/R KMT2Ar Acute LeukemiaDecember 6th 2022
Based on phase 1 data of the AUGMENT-101 trial, the FDA has granted a breakthrough therapy designation to SNDX-5613 for patients with relapsed or refractory KMT2A rearranged acute leukemia.
Study of Ponatinib Versus Imatinib Meets Primary End Point in Ph+ ALLNovember 30th 2022
Takeda Pharmaceuticals announced that the phase 3 PhALLCON trial of ponatinib for Philadelphia-positive acute lymphoblastic leukemia succeeded in improving the rate of minimal residual disease–negative complete remission.
Managing Patients in the Changing Treatment Landscape of ALLNovember 21st 2022
In an interview with Targeted Oncology, Mark R. Litzow, MD, discussed managing patients with different subtypes of ALL and the session he was a part of during the National Comprehensive Cancer Network 2022 Annual Congress: Hematologic Malignancies.
Over 50% of Patients With R/R Acute Leukemias Respond to SNDX-5613 in AUGMENT-101November 4th 2022
Updated data from the phase 1/2 AUGMENT trial led to a 30% complete remission rate and an overall response rate of 53% with SNDX-5613 when used in patients with relapsed/refractory acute leukemias.
Classification, Treatment, and Supportive Care Options in AMLOctober 14th 2022
At the 2022 NCCN: Hematologic Malignancies Conference, a panel discussion gave an overview of current treatment trends for acute myeloid leukemia, as well as supportive care measures to utilize during therapy.
Recent Updates in Diagnosing and Treating Acute Lymphoblastic LeukemiaOctober 11th 2022
In an interview with Targeted Oncology, Kjeld Schmiegelow, MD provided a deep dive into his SOHO 2022 presentation as well as the other acute lymphoblastic leukemia discussions presented during the session.
Treatment of Patients Unfit for Intensive Induction with Venetoclax + AzacitidineAugust 11th 2022
Hetty Carraway, MD, highlights the role of venetoclax + azacitidine in the treatment of patients with acute myeloid leukemia who are unfit for intensive induction therapy.